Sequenom, Inc. (NASDAQ:SQNM) announced that their affiliate companies (Nicox Inc. and Sequenom Laboratories) have entered into an exclusive agreement in the age-related macular degeneration (AMD) field. As part of this agreement, Nicox has been granted the North American promotional rights to the Sequenom Laboratories RetnaGene™ AMD laboratory-developed test, for the evaluation of a patient’s risk of AMD disease progression within 2, 5 and 10 years. The RetnaGene AMD test will be promoted by the same Nicox U.S. sales force which recently launched Sjö™, an advanced diagnostic panel for the early detection of Sjögren’s Syndrome. Nicox expects to begin promoting the RetnaGene AMD test in the United States in the first half of 2014. Sequenom, Inc. (NASDAQ:SQNM) shares after opening at $2.32 moved to $2.52on last trade day and at the end of the day closed at $2.48. Company price to sales ratio in past twelve months was calculated as 1.77 and price to cash ratio as 4.03. Sequenom, Inc. (NASDAQ:SQNM) showed a positive weekly performance of 6.44%.
ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) declared that the European Medicines Agency, or EMA, has decided orphan drug designation for ICT-107 for the treatment of patients by means of glioblastoma. Granting of orphan drug rank in the EU provides sponsor firms with inducements, comprising a 10-year period of market individuality, right of entry to a centralized review process, examination design assistance, and scientific advice during product development, fee reductions, and tax incentives. ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) shares advanced 6.25% in last trading session and ended. the day on $1.26. IMUC return on equity ratio is recorded as- 37.90% and its return on assets is -31.40%. ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) yearly performance is -49.06%.
Oncothyreon Inc (NASDAQ:ONTY) was downgraded by stock analysts at Cantor Fitzgerald from a “buy” rating to a “hold” rating in a report issued on Friday, TheFlyOnTheWall.com reports.Oncothyreon Inc (USA)(NASDAQ:ONTY) shares moved up 6.19% in last trading session and was closed at $3.60, while trading in range of $ 3.19 – 3.62. Oncothyreon Inc (USA)(NASDAQ:ONTY) year to date (YTD) performance is 104.55%.
Prothena Corporation plc (Nasdaq:PRTA) announced that an abstract (Abstract #PB-48) reviewing interim clinical data from its ongoing Phase 1 study of NEOD001 in patients with immunoglobulin light chain (AL) amyloidosis and persistent organ dysfunction will be presented at the XIV International Symposium on Amyloidosis (ISA) in Indianapolis, Indiana. Prothena Corporation PLC (NASDAQ:PRTA) weekly performance is 17.77%. On last trading day company shares ended up $47.39. Prothena Corporation PLC (NASDAQ:PRTA) distance from 50-day simple moving average (SMA50) is 53.81%.